For more than two decades, he was a Managing Director in MF Funds IV-X. During his tenure, he co-managed Mayfield's health care initiative and helped establish the firm’s renowned franchise in health care. He continues his venture investing activities as an angel investor and advisor. Grant Heidrich was the past President of the Western Association of Venture Capital and former member of the Board of Directors of the National Venture Capital Association. Grant also served as Chairman of the Board of Tularik (NASDAQ: TLRK) until it was acquired by Amgen (NASDAQ: AMGN). During his venture career, he has been on the boards of more than 20 public and private companies. In 2009, Grant received the Lifetime Achievement Award from the National Venture Capital Association. He received his B.A. from Stanford University in the Department of Human Biology, and his M.B.A. from Columbia University.
Prior to joining NGM in 2014, Mr. Jonker was the Senior Vice President, Corporate and Business Development at Theravance Biopharma (NASDAQ: TBPH) and held that same role at Theravance, Inc. (NASDAQ: THRX) prior to the spin-out of TBPH. He previously served as the Chief Business Officer of Satori Pharmaceuticals, the Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals prior to its acquisition by Celgene (NASDAQ: CELG) and leadership positions in the business development and legal groups at Genentech. Prior to Genentech, he was an associate in the Technology Transactions Group at Wilson, Sonsini, Goodrich & Rosati, representing clients in the life science and high tech industries. Mr. Jonker holds a J.D. from Columbia University School of Law, an M.LITT. from the University of St. Andrews and a B.A. from Claremont McKenna College.
Arthur D. Levinson, Ph.D.
Dr. Levinson is currently the Chief Executive Officer of Calico and chairman of Apple, Inc. He previously served as Chief Executive Officer of Genentech from 1995 to 2009. Among his significant commitments are his memberships on the Board of Directors of the Broad Institute of the Massachusetts Institute of Technology and the Board of Scientific Consultants of Memorial Sloan-Kettering Cancer Center. Dr. Levinson also served on the Board of Directors of NGM Bio from 2009-2014. Dr. Levinson is the recipient of numerous awards and honors, including the Irvington Institute’s 1999 Corporate Leadership Award in Science, the National Breast Cancer Coalition’s Corporate Leadership Award, Institutional Investor’s Best Biotech CEO award (2004-2007), Princeton University’s James Madison Medal for a distinguished career in scientific research and in biotechnology, Barron’s designation as one of “The World’s Most Respected CEOs” and the Best Practice Institute’s “25 Top CEOs.” Dr. Levinson was elected a fellow to the American Academy of Arts & Sciences in 2008.